Clinical Trial

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Study acronym: Progress
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
Protocol Amendment History 43 amendments
This ClinicalTrials.gov record has been amended 43 times since 2021-10-14; most recent amendment 2026-05-19.
Status change: Not Yet Recruiting → Recruiting 2022-04-06
Trial Details
NCT Number NCT05090891
Lead Sponsor Incyte Corporation
Conditions Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment 98 participants
Start Date 2022-05-05
Primary Completion 2027-07-30 (estimated)
Study Completion 2033-01-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-22